The Robert H. Lurie Comprehensive Cancer Center of Northwestern University in partnership with Feinberg launched an eHealth Distance Learning Portal on August 1 to encourage global collaborations.
Identifying mutations in the estrogen receptor (ER) gene can help clinicians choose effective therapies for patients with ER-positive metastatic breast cancer, according to recent research.
Scientists at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University will test Guardant Health’s technology to detect cancer at early stages in high-risk populations.
Navdeep Chandel, PhD, David W. Cugell Professor of Medicine, has received the National Cancer Institute’s Outstanding Investigator Award to explore how mitochondrial metabolism plays a role in cancer.
The results of a recent study co-authored by C. David James, PhD, uncovered potential new targets for treating glioblastoma, a fatal brain tumor for which there is currently no cure.
New Northwestern Medicine research has shown that reprogrammed stem cells can be used to identify patients with cancer who are likely to experience a dangerous side effect of a common chemotherapy drug.
Lifang Hou, MD, PhD, chief of Cancer Epidemiology and Prevention in the Department of Preventive Medicine, has been named a member of a blue ribbon panel that will help inform the scientific direction of Vice President Joe Biden’s National Cancer Moonshot Initiative.
Two drugs known to improve survival for patients with metastatic renal cell carcinoma do not reduce the risk of cancer recurrence when administered after surgery, according to a recent clinical trial.
Research led by Northwestern Medicine scientist Daniel Foltz, ’01 PhD, sheds light on the assembly of centromeres, a region of the chromosome that helps ensure new cells have 46 chromosomes.
A recent clinical trial conducted by Northwestern Medicine investigator Seema Singhal, MD, showed that the drug daratumumab is a safe and effective treatment for patients with advanced multiple myeloma.